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ABS TRACT
Objective: To evaluate the effects of diabetic ketoacidosis (DKA) on 
neurocognitive functions in children and adolescents presenting with new-
onset type 1 diabetes.
Methods: Newly diagnosed patients were divided into two groups: 
those with DKA and those without DKA (non-DKA). Following metabolic 
stabilization, the patients took a mini-mental status exam prior to undergoing 
a baseline battery of cognitive tests that evaluated visual and verbal cognitive 
tasks. Follow-up testing was performed 8-12 weeks after diagnosis. Patients 
completed an IQ test at follow-up.
Results: There was no statistical difference between the DKA and non-DKA 
groups neither in alertness at baseline testing nor in an IQ test at follow-
up. The DKA group had significantly lower baseline scores than the non-DKA 
group for the visual cognitive tasks of design recognition, design memory and 
the composite visual memory index (VMI). At follow-up, Design Recognition 
remained statistically lower in the DKA group, but the design memory and 
the VMI tasks returned to statistical parity between the two groups. No 
significant differences were found in verbal cognitive tasks at baseline or 
follow-up between the two groups. Direct correlations were present for the 
admission CO2 and the visual cognitive tasks of VMI, design memory and 
design recognition. Direct correlations were also present for admission pH 
and VMI, design memory and picture memory.
Conclusion: Pediatric patients presenting with newly diagnosed type 1 
diabetes and severe but uncomplicated DKA showed a definite trend for 
lower cognitive functioning when compared to the age-matched patients 
without DKA. 
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Introduction
Type 1 diabetes in children and adolescents is associated 
with varying degrees of diminished cognitive function, 
frequently involving memory, but also the subcategories of 
other neuropsychological domains (1,2). Studies have not 
always demonstrated differences in academic performance 
when children with type 1 diabetes are compared to siblings 
or classmates, suggesting that cognitive deficiencies may be 
subtle (3). While the pathogenesis of cognitive decline in patients 
with type 1 diabetes is not well understood, the pathogenesis 
is likely multifactorial based on numerous potential perturbators 
that are present during the crisis of diabetic ketoacidosis 
(DKA). Early age of onset (4), chronic hyperglycemia based on 
hemoglobin A1c (HbA1c) (5), the presence of microvascular 
disease (6) and decreased white matter volume have been 
associated with cognitive deficits (7). Diagnosis before the age 
seven is associated with structural and functional changes in 
the brain (7). Studies vary regarding the relationship between 
significant hypoglycemia in type 1 diabetic children/adolescents 
and a deleterious effect on cognition (8).
DKA is an acute metabolic and immunologic crisis that 
occurs in approximately 25 percent of children in the United 
States with new-onset type 1 diabetes (9). This life-threatening 
emergency results from a deficiency of insulin and insulin 
resistance, systemically (10) and in the brain (11). In addition, 
the endocrine/metabolic decompensation of DKA involves an 
increase in the counter-regulatory hormones (12), resulting in 
progressive hyperglycemia, hyperosmolar dehydration (13), 
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ketoacidosis and the potential for serious electrolyte imbalances 
(14). Increased secretion of cortisol, a counter-regulatory 
hormone and potential neurotoxin, increases the prevalence of 
cognitive impairment in depression (15), an under-recognized 
co-morbidity of type 1 diabetes in children and adolescents (16). 
Glucocorticoid-mediated, reduced hippocampal neurogenesis 
and decreased cognitive function have been reported in the 
streptozotocin (STZ) rat (17). Of importance, the reduced 
hippocampal neurogenesis in STZ mice can be reversed by 
antidepressant treatment (18). Also, a positive correlation 
of C-reactive protein (CRP) with depression, unrelated to 
type 1 diabetes, in children and adolescents supports an 
interaction of emotional stress, systemic inflammation and 
neuroinflammation (19).
In addition to a neurotoxic effect of glucocorticoids, 
support for the physiologic stress of DKA and its treatment 
is also associated with a systemic increase of CRP (20) thus 
supporting roles for both physiologic and psychological stress 
in the pathogenesis of cognition and depression.
A recent cross-sectional retrospective study using a 
computer version of published tasks reported that type 1 diabetic 
children and adolescents who had a history of uncomplicated 
[no clinical cerebral edema (CE)] DKA scored lower in cognitive 
memory tasks of both immediate event-spatial position and 
event-color associations compared to an age-matched group 
without a history of DKA (21). In another cross-sectional 
retrospective study, children with type 1 diabetes were tested 
two to four weeks after either DKA or hypoglycemia, using the 
Stanford-Binet (fourth edition) and recordings of event-related 
potential tests and were compared to age-and sex-matched 
control children without type 1 diabetes. This DKA group also 
had a cognitive deficit (22). 
In this study, we aimed to investigate the contribution of 
DKA to the neurocognitive changes observed in children with 
type 1 diabetes. To avoid the uncertainties of retrospective 
information and its potential influence in the pathogenesis of 
cognitive deficits caused by: 1) the degree and duration of 
hyperglycemia; 2) the frequency/degree of hypoglycemia; 3) 
potential contribution of macro-and microangiopathic changes 
in long-term diabetes; and 4) the comorbidity of depression, 
we conducted this study in newly diagnosed children and 
adolescents presenting with and without DKA and prospectively 
administered a standard and well-validated neurocognitive test 
battery at two points in time. This test battery evaluated: 
visual planning and memory, verbal memory and expressive 
language. The primary outcome was the difference in cognitive 
function based on this test battery.
Methods
Patients between the ages of 7 and 18 years presenting 
to the North Carolina Children’s Hospital with new-onset 
type 1 diabetes were considered for participation. Exclusion 
criteria included non-English speaking patients or parents 
(testing materials were printed in English), chronic medication 
use (except hormone replacement with levothyroxine), 
developmental delay, learning difficulties or neuropsychological 
conditions as reported by parents. Fourteen patients were 
invited to participate between November 2011 and December 
2012. DKA was managed by the pediatric intensive care unit per 
usual protocol, including intravenous insulin and fluid hydration.
The study protocol was approved by institutional review 
board. Patients assented to the study along with parents’ 
consent.  All procedures performed in studies involving human 
participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with 
the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards.
The initial cognitive tests were performed prior to hospital 
discharge. If DKA was present, initial testing occurred at least 
24 hours after DKA resolution (defined as pH≥7.32 and CO2≥18 
meq/L) and transfer to the pediatric ward. Follow-up testing 
(T2) was eight to twelve weeks after the diagnosis of type 1 
diabetes during a follow-up visit to the Pediatric Diabetes Clinic. 
This follow-up testing battery consisted of the same cognitive 
tasks administered at the initial testing as well as a shortened 
measure of intelligence using the Wechsler Abbreviated Scale 
of Intelligence (WASI-IQ).
Measurements and Instruments
Blood chemistries were collected on admission for each 
patient. Blood glucose was monitored prior to cognitive 
tests that were administered in the morning when possible. 
Patients completed a one-hour testing battery administered by 
a psychologist. The initial testing battery consisted of a Mini-
Mental Status Exam (MMSE) to evaluate for alertness prior to 
other testing. This was followed by standard neurocognitive 
tests of visual and verbal cognitive tasks. The visual planning 
and memory tasks used the following instruments: a) Wide 
range assessment of memory and learning, second edition 
(WRAML-2) for design memory, design recognition, picture 
memory and visual memory index (VMI); b) Stanford-Binet for 
bead memory, c) Wechsler Intelligence Scale for Children-IV 
(WISC-IV) for forward spatial span and backward spatial span 
and d) Delis Kaplan Executive Function System (DKEFS) for 
design fluency. The verbal memory and expressive language 
tasks used: a) Wide range assessment of memory and 
learning, second edition for verbal learning, verbal learning recall 
and verbal learning recognition; b) WISC-IV for digit span; and 
c) DKEFS for verbal fluency, with subtests of letter fluency and 
category switching.
Statistical Analysis
Standard scores and composite scores were determined 
for the DKA and the non-DKA groups. A Mann-Whitney U test 
of group medians was used to test for statistical differences 
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between the DKA and non-DKA group’s demographics and 
admission values for HbA1c, heart rate (HR) for degree 
of dehydration, pH, bicarbonate (CO2); MMSE at baseline 
cognitive testing and WASI-IQ at follow-up cognitive testing. 
Statistical differences between the two groups at baseline 
and follow-up testing on the cognitive tasks for visual and 
verbal variables were established using Mann-Whitney U 
test of group medians. Effect size differences (ES-d) for DKA 
and non-DKA across the cognitive tasks for the baseline and 
follow-up testing were also calculated. Chi-square analysis 
was used to identify association between cognitive task 
score changes from baseline to follow-up and DKA/non-DKA 
patient status. Correlations were calculated between cognitive 
tasks measured at baseline (T1) with chemistries obtained at 
admission and between cognitive tasks at baseline or follow-up 
(T2) with pre-test blood glucose.
Results
All patients had uneventful recoveries. No patient required 
mannitol for CE or experienced blood glucose (BG) <70 mg/
dL during hospitalization. Three of 14 invited patients declined 
to participate. Three of the four patients with DKA and five of 
the seven patients without DKA completed follow-up testing. 
Patients with DKA underwent baseline testing 29-34 hours 
after DKA resolution. Patients’ admission parameters and 
demographics are in Table 1. The DKA group presented with 
median labs at diagnosis consistent with DKA. Median HR in 
the DKA group was significantly higher than in the non-DKA 
group: (U=25, p=0.0472). Neither group reached the clinically 
significant BRIEF-Global Executive Composite (GEC) score of 
70, which is suggestive of lower executive functioning. Table 
2 shows mean (standard deviation) and median (range) of 
the standard scores of all cognitive tasks at baseline (T1) and 
follow-up (T2) testing.
At baseline, the DKA group scored lower on several visual 
tasks compared to the group without DKA.
At follow-up, design recognition in the DKA group remained 
statistically lower than the non-DKA group; all of the other visual 
tasks achieved or maintained statistical parity between the two 
groups. There were no significant differences between the DKA 
and non-DKA groups at baseline or follow-up testing for any of 
the verbal tasks (Table 2). The correlation determinations (Table 
3) show statistically significant direct relationships between 
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Table 1. Descriptive variables-group demographics, metabolic/physiologic parameters, mental status and IQ for 11 subjects at admission. Statistical 






Age (years) [mean (SD)] 12.3 (2.6) 12.7 (2.7)
Time (hours) admission to DKA resolution [mean (SD)] 16.8 (7.6) ---
Gender (Male/Female) 2/2 4/3
Physiologic/Metabolic Parameters at admission:
Mean (SD)
Median (Range)































WASI-IQ  (follow-up testing) 107.7 (10.6) 105.2 (11.1)
*Mann-Whitney U test of group medians statistically significant differences for diabetic ketoacidosis vs. non-diabetic ketoacidosis: *1p=0.0472, *2p=0.0138, *3p=0.0104.  
SD: standard deviation, DKA: diabetic ketoacidosis, WASI-IQ: Wechsler Abbreviated Scale of Intelligence 
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Table 2. Neurocognitive tasks. Mean (standard deviation) and median (range) of standard scores of all neurocognitive tasks at baseline and follow-
up testing for diabetic ketoacidosis and non-diabetic ketoacidosis subjects. Statistical differences (*p<0.05) are noted
Neurocognitive Tasks
Baseline Testing (T1) Follow-up Testing (T2)
DKA 
Mean (SD)  
Median (Range)
Non-DKA 
Mean (SD)  
Median (Range)
DKA 
Mean (SD)    
Median (Range)
Non-DKA 
Mean (SD)  
Median (Range)
















































































































  Verbal Fluency (DKEFS)
           Letter Fluency 
           Category Fluency 

























*Mann-Whitney U test of group medians statistically significant differences for diabetic ketoacidosis vs. non- diabetic ketoacidosis: *1p=0.0354,  *2p=0.0495,  *2p=0.0327,  *4p=0.0350. 
WISC-IV: Wechsler Intelligence Scale for Children-IV, WRAML-2: wide range assessment of memory and learning, second edition, VMI: visual memory index, DKEFS: Delis Kaplan 
Executive Function System, DKA: diabetic ketoacidosis
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several admission chemistries and baseline measurements 
of both visual and verbal cognitive tasks. Correlations at 
baseline testing of both visual and verbal cognitive tasks with 
pre-test BGs indicate inverse correlations. At follow-up, the 
visual cognitive task of picture memory maintains its inverse 
correlation with pre-test BG.
Last, chi-square analysis for association of the number of 
cognitive score that increases between baseline and follow-
up showed a significant association (χ2=3.472, p=0.0312) for 
the DKA group. Similarly, the cognitive variables, VMI and digit 
span, had significant inverse correlations with the DKA group 
(r=-0.6635, p=0.0260 and r=-0.7221, p=0.0121, respectively), 
meaning that lower cognitive scores correlate with the DKA 
group.
Discussion
This is the first prospective study to report acute cognitive 
deficits in newly diagnosed children and adolescents with type 
1 diabetes following correction of uncomplicated (no clinical CE) 
DKA. Our data support a neuronal insult during the metabolic 
and immunologic crisis of DKA and/or its treatment that results 
in acute and possibly long-term cognitive deficits. We recorded 
statistically lower median baseline (T1) task scores in three of 
the eight visual cognitive tasks tested in the newly diagnosed 
DKA group in comparison to an age-matched newly diagnosed 
non-DKA group. Whether the improvement in design memory 
and VMI scores three months (T2) after the correction of 
DKA are final new baselines is unknown, since the follow-up 
tasks were performed at a time when brain remodeling was 
possibly occurring (23). These longitudinal results differ from 
the retrospective, cross-sectional, solitary time point studies 
that reported color and position associations in children and 
adolescents with a history of DKA that were believed to 
indicate permanent cognitive deficits (21). In contrast, the 
follow-up (T2) testing of the median task score for design 
recognition in the DKA group decreased further from the 
baseline; however, for the non-DKA group, the score remained 
constant. This is in keeping with previous speculation that the 
neurotoxic milieu of DKA initiates a greater insult than cognitive 
deficit with only hyperglycemia. A pattern of decreasing 
cognition with time is also in keeping with the proton-magnetic 
resonance spectroscopy (MRS) study of recurrent episodes of 
DKA in a teenage patient, where the NAA/Cr ratio (neuronal 
insult) decreased during each DKA treatment, followed by a 
lesser recovery after correction of the second episode of DKA; 
cognitive testing was not reported (24).
The combined admission CO2 and pH of the DKA and 
non-DKA groups versus the T1 results of the visual and verbal 
cognitive tasks (Table 3) showed significant direct correlation 
with six baseline tasks; design recognition, design memory, 
picture memory and VMI as did verbal learning and category 
fluency. These correlations are in keeping with the association 
of an acute neuronal insult in close proximity to the T1 cognitive 
tasks and also supportive of the direct correlation between 
the admission level of consciousness and admission pH at 
the time of DKA (25). However, it should be noted that we 
found no correlation between the Glasgow coma score and 
cognitive testing, nor a difference between the mini-alertness 
tests prior to cognitive testing of the DKA and non-DKA groups. 
In addition, the visual tasks of bead memory, picture memory 
and VMI and the verbal task of digit span had an inverse 
correlation with the pre-test (T1) BG. An inverse correlation 
was also present for picture memory and the pre-test (T2) 
BG. This inverse pre-test BG correlation with cognitive tasks 
Table 3. Statistically significant (p<0.05) correlations for 
neurocognitive tasks measured at baseline (T1) and follow-up (T2), 
with chemistries and heart rate measured at admission and blood 
glucose at T1 or T2
Variable Correlation Relationship Correlation r (p)
Baseline Cognitive Tasks (T1): Admission Chemistry
Visual Cognitive Tasks
Design recognition: CO2  0.6374 (0.0245)
VMI: CO2  0.6820 (0.0208)
Design memory: CO2  0.6348 (0.0441)
Design memory: pH  0.7619 (0.0134)
Picture memory: pH  0.6213 (0.0281)
VMI: pH  0.8368 (0.0013)
Design recognition: HR - 0.6855 (0.0199)
Verbal Cognitive Tasks
Verbal learning: CO2  0.6114 (0.0456)
Verbal learning: pH  0.6721 (0.0234)
Category fluency: pH  0.6576 (0.0279)
Baseline Cognitive Tasks (T1): Pre-test BG 
Visual Cognitive Tasks
Bead memory: BG - 0.8034 (0.0295)
Picture memory: BG - 0.7708 (0.0425)
VMI: BG - 0.7476 (0.0450)
Verbal Cognitive Tasks Digit span: BG - 0.6744 (0.0463)
Follow-up Cognitive Tasks (T2): Pre-test BG 
Visual Cognitive Tasks Picture memory: BG - 0.8881 (0.0442)
BG: blood glucose, VMI: visual memory index
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in our study was not present in the study by Ghetti et al (21). 
While it is not statistically significant, it is important to note 
that there was a large difference (effect size=2.5) between 
the admission HbA1c in our DKA and non-DKA groups 
suggesting that the cases with DKA had longer and/or more 
severe hyperglycemia at the time of testing. However, no 
correlation was found between HbA1c levels and cognitive 
testing in our study. In addition, there was no difference in 
the HbA1c pre-test values of DKA and non-DKA groups in 
the study by Ghetti et al (21).
Although the pathogenesis of the cognitive deficiencies 
associated with DKA requires further study, it has been reported 
that ketone bodies, by-products of metabolic dysregulation, 
are capable in-vitro of differentially perturbating cerebral 
capillary endothelial cells (CCEC) (26) and the increased 
release of vasoactive peptides such as endothelin-1 (ET-1) 
(27) and vascular endothelial growth factor (VEGF) (28) that 
negatively impacts cognition. Hyperlipoproteinemia (29) and 
toxic tryptophan catabolites (30) are additional by-products 
of DKA metabolic dysregulation and its treatment and thus 
candidates to affect cognition. 
Also, 3-deoxyglucosone (31) and methylgloxal (32), the 
highly reactive carbonyl compounds and neurotoxins, are 
precursors of advanced glycation end-products (AGE) that 
increase during treatment and up-regulate the inflammatory 
milieu of DKA (33).
These by-products are unlikely to be the sole candidates 
of neuronal insult/deficit since the milieu in children and 
adolescents with severe DKA also increases systemic 
and cerebral oxidative stress (34,35), SIR (36) and a 
likely neuronal insult. Systemic inflammatory cytokines, 
activation of the complement cascade including C5b-9, 
the membrane attack complex (37) and CRP (20) are part 
of the innate immune response activated by DKA that 
increases during treatment. Evidence for an acute neuronal 
insult by oxidative stress and inflammatory peptides is the 
immune cytochemistry (ICC) study of autopsied brains of 
adolescents with type 1 diabetes, where death occurred 
due to DKA/CE. These cases had histories of chronic poor 
diabetic control and poor school performance along with 
significant cerebral expression of oxidative/nitrosative stress 
and lipid peroxidation (35), as well as an acute inflammatory 
insult, based on glial and CCEC activation, expression of 
inflammatory peptides and neuronal deficits (11,38,39). 
It is important to recognize that the neurotoxic immune 
phenotype in the brains with fatal DKA/CE is similar not 
only to the SIR of clinical DKA (36,37), but it also develops 
over time in type 1 diabetic rodent models, without the 
acute metabolic and immunologic insults of DKA and the 
occurrence of CE (40). The latter is in keeping with Hood et 
al’s clinical study (41) and thus DKA and CE do not appear 
to be prerequisites for neuronal and cognitive deficits, but 
rather additional severe insults. A sustained cognitive injury 
is also suggested based on: 1) the infrequent reports of 
immediate cognitive deficits following severe DKA (23); 
2) the extended and increased systemic concentration 
of inflammatory cytokines even after correction of DKA 
(36); 3) the decreased density of neuroprotective GH and 
IGF-1 neuronal receptors in various brain regions including 
the hippocampus in DKA/CE (11,38,39), a region that is 
important for the formation and retrieval of numerous 
memory systems. The neuroinflammatory phenotype in 
the BB/W type 1 diabetic rat (40); and perhaps most 
importantly; 4) the activation of the AGE/receptor for 
advanced glycation end products (RAGE), an amplifier 
and perpetuator of oxidative stress and dysregulation of 
inflammatory pathways in the brain with or without DKA 
(39,40). A progressive and sustained cognitive injury also 
supports; 5) The observation that children whose DKA was 
in the more distant past had a poorer memory performance 
(21). 
Limitations of this study are the small sample size, the 
short duration of follow-up and the absence of testing non-
diabetic children and adolescents. Strengths of the study 
are that: 1) It is a prospective study involving patients of 
comparable ages with newly diagnosed type 1 diabetes 
with and without DKA; 2) It eliminates the confounding 
factors of hypoglycemia and microvascular disease; 3) It 
uses standardized cognitive testing; 4) It reports short-
term follow-up testing; 5) It extends our insight into the 
subtleties of the early cognitive deficits in young patients 
with new-onset type 1 diabetes and DKA; and 6) It shows 
the importance of longitudinal testing. 
Understanding the physiological and functional changes 
that accompany DKA may contribute to early detections 
of brain changes associated with DKA, prior to the onset 
of chronic debilitating effects of type 1 diabetes and may 
inform about the mechanisms associated with subsequent 
cognitive decline. Modalities to study the effect of diabetes 
on the brain have evolved over the years and provide new 
opportunities not only to examine the impact of DKA on 
neurocognitive dysfunction but also to understand the 
underlying mechanisms. Therefore, further studies in larger 
populations using new static and functional neuroimaging 
tools are needed. Nevertheless, this study serves to 
encourage the careful follow-up, preferably in a coordinated 
care setting, of all children/adolescents with type 1 diabetes, 
especially those who have had DKA. Whether routine 
neurocognitive testing can be recommended in children 
with type 1 diabetes as part of their follow-up is an 
important question that remains to be answered. 
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